Acacia Pharma commercially launches BARHEMSYS® in the US for the treatment of prevention of postoperative nausea & vomiting
24 augustus 2020
Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces today that BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors. BARHEMSYS was approved by the US Food and Drug Administration (FDA) for the treatment and prevention of postoperative nausea & vomiting (PONV) on 26 February 2020.
“We are excited to announce today that BARHEMSYS is now available in the US for the millions of patients each year who suffer from PONV,” commented Mike Bolinder, Acacia Pharma’s CEO. “BARHEMSYS is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed prior prophylaxis with an agent of a different class using current standard of care and we estimate there are approximately 16 million such surgical patients each year in the US that go on to suffer from PONV despite receiving prophylaxis. We believe there will be strong demand for BARHEMSYS as US healthcare institutions seek to address surgical backlogs created by the coronavirus crisis and are very happy to make this new therapy available in the US.”
BARHEMSYS is now available for ordering in the US through the major wholesalers and selected specialty distributors, including Cardinal Health, Amerisource Bergen, Besse, McKesson, McKesson Medsurg, Morris and Dickson, and Curascript.